GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma

$552,266
Chun Li · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer Progression

$552,256
Kenneth J. Pienta · University Of Michigan At Ann Arbor · U01 · FY2011 · CA

Optimizing Novel Immunotherapy Combinations Targeting the Tumor Microenvironment in Canine Spontaneous Osteosarcoma

$552,171
Steven W. Dow · Colorado State University · U01 · FY2022 · CA

A deubiquitination module controls Treg adaptation to tumor microenvironment

$552,115
Deyu Fang · Northwestern University At Chicago · R01 · FY2023 · CA

Re-wiring PDAC Tumor Immunity Through Dendritic Cells

$551,987
David G Denardo · Washington University · R01 · FY2021 · CA

Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells

$551,974
Wendell A Lim · University Of California, San Francisco · R01 · FY2023 · CA

Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma

$551,927
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA

Modulation of the tumor microenvironment with probiotic therapies

$551,862
Tal Danino · Columbia Univ New York Morningside · R01 · FY2023 · CA

Dynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer

$551,809
Joanna E Burdette · University Of Illinois At Chicago · R01 · FY2019 · CA

Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture

$551,690
Simone Krebs · Sloan-Kettering Inst Can Research · R37 · FY2022 · CA

CANCAN-RUTGERS

$551,676
Eileen White · Rutgers Biomedical And Health Sciences · OT2 · FY2023 · CA

EPHA2 Receptor Signaling in Breast Cancer Mechanotransduction

$551,618
Elena B Pasquale · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2022 · CA

Developing isoform-selective Hsp90 inhibitors for monotherapy and enhanced immunotherapy against lethal prostate cancer

$551,601
Brian S J Blagg · University Of Notre Dame · R01 · FY2025 · CA

Differential TGF-Beta Signaling in Bone Microenviroment: Impact on Tumor Growth

$551,442
Theresa A Guise · Indiana University Indianapolis · U01 · FY2011 · CA

Targeting Lipid Unsaturation in Ovarian Cancer Stem Cells

$551,416
Daniela E Matei · Northwestern University At Chicago · R01 · FY2019 · CA

Hyperplexed Quantum Dots for Multidimensional Cell Classification in Intact Tissue

$551,348
Andrew Michael Smith · University Of Illinois At Urbana-Champaign · R01 · FY2023 · EB

Modeling the role and regulation of reactive stroma in breast ductal carcinoma microinvasions

$551,254
Katarzyna Anna Rejniak · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA

Overcoming obesity-associated immunotherapy resistance in renal cancer

$551,148
Lyse A Norian · University Of Alabama At Birmingham · R01 · FY2023 · CA

Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices

$551,095
Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA

Innate lymphoid cell regulation of the host-microbiota interactions in cancer

$551,090
Gregory F Sonnenberg · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA

CANCAN-RUTGERS

$551,024
Eileen White · Rutgers Biomedical And Health Sciences · OT2 · FY2025 · CA

Systems analysis of cell-cell communication networks and immune activity in the melanoma tumor microenvironment

$551,007
Kathryn Miller-Jensen · Yale University · U01 · FY2022 · CA

Predicting Prostate Cancer Aggressiveness

$550,965
Alexander Robertson Allan Anderson · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2015 · CA

Olympus FV1000MPE Multiphoton Microscope

$550,894
Teng-Leong Chew · Northwestern University At Chicago · S10 · FY2012 · OD

Development of microRNA (miR)-based cell-targeted polymeric nanoparticles for myeloma therapy

$550,877
Ruben D Carrasco · Dana-Farber Cancer Inst · R01 · FY2025 · CA